Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.04 per share and revenue of $59.94 million for the quarter.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH opened at $7.99 on Wednesday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.14 billion, a P/E ratio of -53.26 and a beta of 1.22. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.67. The firm has a 50-day moving average price of $8.47 and a two-hundred day moving average price of $7.66.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 10th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.